Community
Advertising Opportunities
Biotechnology Europe Programs
Biotechnology Europe Community
Feedback
Contact
Biotechnology Europe Advantages
Advertising Opportunities on Biotechnology Europe
Sponsorship Opportunities on Biotechnology Europe
Post a Job on Biotechnology Europe
Post a Company Profile on Biotechnology Europe
Post a News on Biotechnology Europe
Post an Event on Biotechnology Europe
Post a Product on Biotechnology Europe
Post a Publication on Biotechnology Europe
Post a Technology on Biotechnology Europe
Post a Resume on Biotechnology Europe
Terms of Business
Imprint
Privacy Policy
FAQ
Subscribe Newsletter
30.06.2008 Headline results of Flurizan® in clinical phase III trial
25.06.2008 An Update to Dako's Autostainer Link
16.06.2008 Azilect® slows the progression of Parkinson's disease in clinical trial
22.05.2008 Lundbeck acquires European commercialization rights for Flurizan® from Myriad, USA - a new drug in final phase III development for the treatment of Alzheimer's disease
13.05.2008 Circadin launch rollout starts with the launch of the product in the important German market
29.04.2008 Ulf Wiinberg appointed new CEO of Lundbeck
23.04.2008 New incentive plan in the Lundbeck Group
05.03.2008 Claus Bræstrup resigns as President and CEO of Lundbeck
18.02.2008 Lundbeck further strengthens pipeline by moving Lu AA34893 into clinical phase II
28.01.2008 Dako partners with General Data to increase patient safety
24.09.2007 Lundbeck in-licenses Circadin®, a drug approved for the treatment of primary insomnia from Neurim Pharmaceuticals
05.09.2007 Federal appeals court upholds Lexapro® patent decision
